PT-112 in Subjects With Thymoma and Thymic Carcinoma | MicrobiomeTrials← Back to trialsNCT05104736
PT-112 in Subjects With Thymoma and Thymic Carcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-04-06Est. Completion: 2027-12-31
Enrollment target: 53 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal CellCarcinoma, Ovarian EpithelialNasopharyngeal CarcinomaCarcinoma, ThymicAnal CancerMesotheliomaEsophagogastric CancerHigh Microsatellite Instability Colorectal CarcinomaSquamous Cell Carcinoma of Head and NeckTriple Negative Breast Neoplasms
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembro…
Boston, United StatesEst. completion Oct 5, 2027
Thymic Epithelial TumorRecurrent ThymomaThymic Cancer
Background:
Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatm…
Bethesda, United StatesEst. completion Dec 31, 2026